This OHE publication is intended to inform and stimulate debate about the way different sorts of evidence and considerations are taken into account in decisions about new health care technologies. The authors argue for greater use of multiple criteria decision analysis (MCDA) as an aid to decision-making that is based on health technology assessment.
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would replace the current PPRS system. The implications for pricing and reimbursement, and innovation, are outlined by Prof Towse in this blog post.
Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof Nancy Devlin, OHE’s Director of Research.
The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of Health (Bundesgesundheitsministerium). The main findings of the Australian study are outlined in this post.
The OHE has just published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of Health (Bundesgesundheitsministerium). The main findings of the UK study are outlined in this post.
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article in the British Journal of Clinical Pharmacology, Prof Adrian Towse examines the issues from a UK perspective. Managing and containing costs in the NHS is a perennial challenge. Far less clear is how to accomplish this while still ensuring sufficient incentives for timely access to new medical therapies, particularly new medicines.
Debate continues about the methods that the UK’s NICE uses in its appraisals of medical technologies, including whether effects beyond the NHS should be considered using a cost-benefit approach. Examining economic appraisal guidelines issued by other official agencies offers an important opportunity to set NICE’s perspective in context. Ruth Puig-Peiró, an economist at the OHE, is engaged in research that examines how and how much various official UK guidelines differ.
QALY measures have become important tools in valuing health interventions so that resource allocations can be made. Current methods, however, may not adequately capture QALYs for cancer patients, particularly in the last years of life. This post reviews the issues and suggests next steps.
HTAinSite is a unique resource that enables subscribers to quickly find relevant information on NICE technology appraisal (TA) decisions and the evidence used to support them. Launched in May 2009, the project is a collaboration involving the OHE, City University London and Abacus International.